Zeus advises on USD130m deal for Brabant Pharma
Drug development firm Brabant Pharma has been sold to US-based pharmaceutical company Zogenix, in a deal where the main selling shareholders were advised by Zeus Capital. Consideration for the deal is expected to reach up to USD130m. Brabant is a single purpose company developing its low-dose fenfluramine treatment to



